REG - Inspiration Health - Directorate Change

Inspiration HealthcareAnnouncement

28/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240528:nRSb9380Pa&default-theme=true

RNS Number : 9380P  Inspiration Healthcare Group PLC  28 May 2024

28 May 2024

The information contained within this announcement is deemed by the Company to
constitute inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by the Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to be in the
public domain.

 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

Board Changes

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology
company pioneering best-in-class, specialist neonatal intensive care medical
devices, announces the following board changes.

 

Neil Campbell will step down as CEO of Inspiration Healthcare on 30 May 2024
and become a Non-Executive Director of the Company.  He will formally leave
full time employment with the Company at the end of June and become a
consultant to the business as a Global Advocate supporting key relationships
and business development opportunities.  Neil has been with the Group for
over 20 years having been one of the original founders of Inspiration
Healthcare and was appointed as CEO of the Group in June 2015.

 

At the request of the Board, Roy Davis, Non-Executive Chair is to become
Executive Chairman and Interim CEO of the Company.

 

Roy brings a wealth of commercial experience in medical devices companies and
has a proven track record of successfully scaling companies and delivering
substantial value for shareholders.  His expertise includes delivering sales
growth strategies, transforming business operations, enhancing operational
efficiency, and increasing productivity to yield higher profits.  He has held
leadership positions at a number of publicly quoted med tech companies,
including as Non-Executive Chair at Medica Group plc, a leading UK
tele-radiology company until its acquisition by IK partners for £269m in
2024.  He was also CEO of Optos plc, a leading retinal imaging device
manufacturer from 2008 to 2016 until its sale to Nikon for $400 million in
2015 and CEO of Gyrus Group plc, a leader in minimally invasive surgery and
visualisation, until its acquisition by Olympus Corporation in 2008 for $1.9
billion.

 

Commenting on the change, Roy Davis, Executive Chairman said:

 

"Neil has played an important role over the last 20 years in founding the
business, as a dedicated member of the Inspiration team and as Board member.
 I would like to thank Neil for his tireless commitment to the business and
look forward to his continued involvement as a Non-Executive Director and
advisor going forward. In becoming Executive Chairman and Interim CEO I look
forward to working with the team to help Inspiration Healthcare on the next
stage of its journey and to achieving its full potential."

 

Neil Campbell commented:

 

"I am pleased to be able to transition from an executive to a Non-Executive
role with Inspiration Healthcare. While the business has experienced some
challenges in recent times, I am incredibly proud of what we have achieved
from start-up 20 years ago to where it is today.  I look forward to being
able to continue to contribute to the business as a Non-Executive Director."

 

The Board will keep shareholders updated on the process to appoint a permanent
CEO in due course.

 

 

 

For further information, please contact:

 

 Inspiration Healthcare Group plc                                                Tel: +44 (0)330
                                                 175 0000
 Roy Davis, Executive Chairman

 Alan Olby, Chief Financial Officer

 Liberum (Nominated Adviser & Broker)                                            Tel: +44 (0)20
                                                 3100 2000
 Phil Walker

 Richard Lindley

 Will King

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
 Anna Dunphy                                     Mob: +44 (0) 7876 741 001
 Stephanie Cuthbert                              Mob: +44 (0) 7796 794 663
 Louis Ashe-Jepson                               Mob: +44 (0) 7747 515 393

 

 

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering
medical technology. Based in the UK, the Company specialises in neonatal
intensive care medical devices, which are addressing a critical need to help
to save the lives and improve the outcomes of patients, starting with the very
first breaths of life.

 

The Company has a broad portfolio of its own products and complementary
distributed products, for use in neonatal intensive care designed to support
even the most premature babies throughout their hospital stay. Its own branded
products range from highly sophisticated capital equipment such as ventilators
for life support through to single-use disposables.

 

The Company sells its products directly to hospitals and healthcare providers
in the UK and Ireland, where it also distributes a range of advanced medical
technologies for infusion therapy.  In the rest of the world the Company has
an established network of distribution partners around the world giving access
to more than 75 countries.

 

The Company operates in the UK from its world-class Manufacturing and
Technology Centre in Croydon, South London and from its facility in Hailsham,
East Sussex, and in the USA from its facility in Melbourne, Florida.

 

Further information on Inspiration Healthcare can be found at
www.inspirationhealthcaregroup.com (http://www.inspirationhealthcaregroup.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABGGDURUDDGSU